Diffuse Non-midline Glioma with H3F3A K27M Mutation: a Prognostic and Treatment Dilemma

Overview

Journal Acta Neuropathol Commun

Publisher Biomed Central

Specialty Neurology

Date 2017 May 17

PMID 28506301

Citations 25

Authors

Giselle Lopez

Nancy Ann Oberheim Bush

Mitchel S Berger

Arie Perry

David A Solomon

Affiliations

Soon will be listed here.

Citing Articles

Molecular and Pathological Features of Paediatric High-Grade Gliomas.

Blasco-Santana L, Colmenero I Int J Mol Sci. 2024; 25(15).

PMID: 39126064 PMC: 11312892. DOI: 10.3390/ijms25158498.

Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort.

Hayashi N, Fukai J, Nakatogawa H, Kawaji H, Yoshioka E, Kodama Y Acta Neuropathol Commun. 2024; 12(1):120.

PMID: 39061104 PMC: 11282756. DOI: 10.1186/s40478-024-01808-w.

Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?.

Donev K, Sundararajan V, Johnson D, Balan J, Chambers M, Paulson V J Neuropathol Exp Neurol. 2024; 83(5):357-364.

PMID: 38447592 PMC: 11029465. DOI: 10.1093/jnen/nlae018.

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.

Odia Y, Hall M, Cloughesy T, Wen P, Arrillaga-Romany I, Daghistani D Neuro Oncol. 2024; 26(Supplement_2):S165-S172.

PMID: 38386699 PMC: 11066928. DOI: 10.1093/neuonc/noae021.

Does H3K27M Mutation Impact Survival Outcome of High-Grade Spinal Cord Astrocytoma?.

Zhang F, Cheng L, Ding Z, Wang S, Zhao X, Zhao Z Neurospine. 2024; 20(4):1480-1489.

PMID: 38171314 PMC: 10762395. DOI: 10.14245/ns.2346650.325.

References

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

Schwartzentruber J, Korshunov A, Liu X, Jones D, Pfaff E, Jacob K . Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012; 482(7384):226-31. DOI: 10.1038/nature10833. View

Sturm D, Witt H, Hovestadt V, Khuong-Quang D, Jones D, Konermann C . Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012; 22(4):425-37. DOI: 10.1016/j.ccr.2012.08.024. View

Wu G, Diaz A, Paugh B, Rankin S, Ju B, Li Y . The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014; 46(5):444-450. PMC: 4056452. DOI: 10.1038/ng.2938. View

Nguyen A, Colin C, Nanni-Metellus I, Padovani L, Maurage C, Varlet P . Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours. Neuropathol Appl Neurobiol. 2014; 41(3):403-8. DOI: 10.1111/nan.12196. View

Feng J, Hao S, Pan C, Wang Y, Wu Z, Zhang J . The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. Hum Pathol. 2015; 46(11):1626-32. DOI: 10.1016/j.humpath.2015.07.002. View

Solomon D, Wood M, Tihan T, Bollen A, Gupta N, Phillips J . Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations. Brain Pathol. 2015; 26(5):569-80. PMC: 6055926. DOI: 10.1111/bpa.12336. View

Orillac C, Thomas C, Dastagirzada Y, Teresa Hidalgo E, Golfinos J, Zagzag D . Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation. Acta Neuropathol Commun. 2016; 4(1):84. PMC: 4983033. DOI: 10.1186/s40478-016-0361-0. View

Pages M, Beccaria K, Boddaert N, Saffroy R, Besnard A, Castel D . Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Brain Pathol. 2016; 28(1):103-111. PMC: 8028391. DOI: 10.1111/bpa.12473. View

10.

Kline C, Joseph N, Grenert J, Van Ziffle J, Talevich E, Onodera C . Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro Oncol. 2017; 19(5):699-709. PMC: 5464451. DOI: 10.1093/neuonc/now254. View